Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV-IVIG prophylaxis after allogeneic hematopoietic stem cell transplantation
ChiCTR2100050438Phase 4Recruiting
- Sponsor
- Suzhou Hongci Hematology Hospital
- Start
- Aug 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of human cytomegalovirus immune globulin and immune serum globulin in cytomegalovirus disease (CMV) (2 arms), sponsored by Suzhou Hongci Hematology Hospital. Primary endpoint: Proportion of subjects with CMV reactivation by 100 days after transplantation. Started Aug 2021; status: recruiting.
02
Drugs
human cytomegalovirus immune globulinimmune serum globulin
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on ChiCTR2100050438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050438.